COVID-19 and corticosteroids: a narrative review.
Gaber El-Saber BatihaAli I Al-GareebHebatallah M SaadHayder M Al-KuraishyPublished in: Inflammopharmacology (2022)
It has been reported that corticosteroid therapy was effective in the management of severe acute respiratory syndrome (SARS) and the Middle East Respiratory Syndrome (MERS), and recently in coronavirus disease 2019 (COVID-19). Corticosteroids are potent anti-inflammatory drugs that mitigate the risk of acute respiratory distress syndrome (ARDS) in COVID-19 and other viral pneumonia, despite a reduction of viral clearance; corticosteroids inhibit the development of cytokine storm and multi-organ damage. The risk-benefit ratio should be assessed for critical COVID-19 patients. In conclusion, corticosteroid therapy is an effective way in the management of COVID-19, it reduces the risk of complications primarily acute lung injury and the development of ARDS. Besides, corticosteroid therapy mainly dexamethasone and methylprednisolone are effective in reducing the severity of COVID-19 and associated comorbidities such as chronic obstructive pulmonary diseases (COPD), rheumatoid arthritis, and inflammatory bowel disease (IBD).
Keyphrases
- coronavirus disease
- sars cov
- acute respiratory distress syndrome
- respiratory syndrome coronavirus
- extracorporeal membrane oxygenation
- rheumatoid arthritis
- mechanical ventilation
- high dose
- low dose
- stem cells
- pulmonary hypertension
- case report
- lipopolysaccharide induced
- systemic lupus erythematosus
- anti inflammatory
- anti inflammatory drugs
- ulcerative colitis
- lps induced
- ankylosing spondylitis
- respiratory failure
- air pollution
- drug induced
- replacement therapy
- community acquired pneumonia